Intimation of acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Jul 2026, 09:30 PM IST · BSE ID: b9355436-b8f8-4202-9f20-fa54d8404789
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's subsidiary is buying 80% of A1 Biochem Group's drug research services for USD 17 million.
🤖 AI Summary
- Aurobindo Pharma's subsidiary, Apitoria Pharma, approved acquiring 80% ownership in A1 Biochem Group for USD 17 million.
- A1 Biochem Group provides Contract Research Services, including custom synthesis and medicinal chemistry, primarily in the USA.
- The acquisition includes A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.
- A1 Biochem Group reported a turnover of INR 1,024.42 Mn and an EBITDA of INR 465.46 Mn in FY2025-26.
- The transaction aligns with Aurobindo Pharma's strategic objectives in the Pharmaceuticals industry.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Value
USD 17 million
A1 Biochem Group Turnover FY2025-26
INR 1,024.42 Mn
A1 Biochem Group EBITDA FY2025-26
INR 465.46 Mn
Ownership acquired in A1 Biochem Group
80%
🏢 How This Affects the Company
The acquisition expands Aurobindo Pharma's presence in Contract Research Services, adding chemistry services for pharmaceutical and biotech companies. It integrates A1 Biochem's laboratories in the USA and India into Apitoria's operations.
The acquisition involves an enterprise value of USD 17 million, impacting the balance sheet with a new asset and associated cash outflow. A1 Biochem Group's turnover of INR 1,024.42 Mn and EBITDA of INR 465.46 Mn in FY2025-26 will be consolidated.
Aurobindo Pharma gains two scientific laboratories and a team of 90+ scientists, enhancing its capabilities in custom synthesis, medicinal chemistry, and process scale-up services. Dr. Rajendra Gadikota will continue to lead the acquired group.
The acquisition does not fall under related party transactions, and promoters have no interest in the acquired entity, mitigating related-party risks. Integration risks associated with acquiring a CRO business remain.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this filing.
👤
Who Is Affected
Existing shareholders are affected by the company's strategic decision to expand into Contract Research Services, which entails a USD 17 million investment by a subsidiary.
🔍
Management Signal
This decision reveals management's intent to strengthen Aurobindo Pharma's position in pharmaceutical contract research through strategic acquisitions and diversification within the industry.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Aurobindo Pharma's Q1 FY2027 results — monitor consolidated financial performance.
Subsequent filings regarding the integration of A1 Biochem Group.
Details on synergy realization from the acquired Contract Research Services business.
LOW RISK
The acquisition does not involve related party transactions, as confirmed in the filing.
💡 Investor Takeaway
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma, is acquiring 80% of A1 Biochem Group for USD 17 million. A1 Biochem Group reported INR 1,024.42 Mn turnover and INR 465.46 Mn EBITDA in FY2025-26, expanding the company's Contract Research Services capabilities.
⚖️ Strengths & Concerns
✅ Positives
- A1 Biochem Group generated a turnover of INR 1,024.42 Mn in FY2025-26, adding a revenue stream to Aurobindo Pharma's subsidiary.
- The acquired group recorded an EBITDA of INR 465.46 Mn in FY2025-26, indicating a profitable business operation.
⚠️ Concerns
- The specific financial impact on Aurobindo Pharma's overall margins post-acquisition is not detailed in the filing.
- No information is provided on A1 Biochem Group's historical revenue or profit growth, limiting comparative analysis.
📅 Company Track Record
Aurobindo Pharma has recently completed several strategic transactions, including establishing an Indonesian subsidiary in July 2026 and acquiring Lannett Company, Inc., USA in June 2026. This latest acquisition continues a pattern of inorganic growth initiatives.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the acquisition value of A1 Biochem Group by Aurobindo Pharma's subsidiary?
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, approved the acquisition of 80% ownership in A1 Biochem Group for an enterprise value of USD 17 million.
What was the turnover of A1 Biochem Group in FY2025-26?
A1 Biochem Group generated a turnover of INR 1,024.42 Mn in FY2025-26.
What was the EBITDA of A1 Biochem Group in FY2025-26?
A1 Biochem Group recorded an EBITDA of INR 465.46 Mn in FY2025-26.
What percentage ownership is Aurobindo Pharma's subsidiary acquiring in A1 Biochem Group?
Apitoria Pharma Private Limited will hold 80% ownership in A1 Biochem Labs (India) Private Limited, which will in turn control the A1 Biochem Group businesses.
Which entities are part of the A1 Biochem Group acquisition?
The A1 Biochem Group comprises A1 Biochem Labs (India) Private Limited, the business of A1 Biochem Research (India) Private Limited, and A1 Biochem Labs LLC, USA.
Questions based on this BSE filing only. For information purposes.